Cargando…
Cutaneous adverse effects of the available COVID-19 vaccines
Vaccination has played a crucial role in the improvement of global health. Some of the world’s deadliest diseases, like smallpox and rinderpest, have been eradicated with the help of vaccines, and many others have been restrained. The appearance of the strain of coronavirus disease 2019 (COVID-19) s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076732/ https://www.ncbi.nlm.nih.gov/pubmed/34518015 http://dx.doi.org/10.1016/j.clindermatol.2021.04.001 |
_version_ | 1783684743939751936 |
---|---|
author | Bogdanov, Georgi Bogdanov, Ivan Kazandjieva, Jana Tsankov, Nikolai |
author_facet | Bogdanov, Georgi Bogdanov, Ivan Kazandjieva, Jana Tsankov, Nikolai |
author_sort | Bogdanov, Georgi |
collection | PubMed |
description | Vaccination has played a crucial role in the improvement of global health. Some of the world’s deadliest diseases, like smallpox and rinderpest, have been eradicated with the help of vaccines, and many others have been restrained. The appearance of the strain of coronavirus disease 2019 (COVID-19) severe acute respiratory syndrome coronavirus 2 and its impact on global health have made the development of effective and safe vaccines crucial for this new lethal disease. So far, there are three main types of COVID-19 vaccines in use around the world: messenger RNA–based vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines. Some of them have passed through phase 3 of safety and efficacy trials and are widely used for prophylaxis of COVID-19 infection. A plethora of cutaneous adverse events have been reported, most of them mild or moderate injection-site reactions. Some rare delayed inflammatory reactions such as “COVID arm” have also been reported, posing questions on their pathophysiology and clinical importance. Some rare serious adverse events, such as vaccine-induced prothrombotic immune thrombocytopenia and anaphylaxis, have been described raising great concerns on the safety of some widely spread vaccines. More data need to be collected with further and more detailed analysis. The overall risk of such severe adverse reactions remains extremely low, and the benefits of the existing vaccines in combating the widespread threat of COVID-19 continue to outweigh the risk of their side effects. |
format | Online Article Text |
id | pubmed-8076732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80767322021-04-27 Cutaneous adverse effects of the available COVID-19 vaccines Bogdanov, Georgi Bogdanov, Ivan Kazandjieva, Jana Tsankov, Nikolai Clin Dermatol COVID-19: Important Updates and Developments Vaccination has played a crucial role in the improvement of global health. Some of the world’s deadliest diseases, like smallpox and rinderpest, have been eradicated with the help of vaccines, and many others have been restrained. The appearance of the strain of coronavirus disease 2019 (COVID-19) severe acute respiratory syndrome coronavirus 2 and its impact on global health have made the development of effective and safe vaccines crucial for this new lethal disease. So far, there are three main types of COVID-19 vaccines in use around the world: messenger RNA–based vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines. Some of them have passed through phase 3 of safety and efficacy trials and are widely used for prophylaxis of COVID-19 infection. A plethora of cutaneous adverse events have been reported, most of them mild or moderate injection-site reactions. Some rare delayed inflammatory reactions such as “COVID arm” have also been reported, posing questions on their pathophysiology and clinical importance. Some rare serious adverse events, such as vaccine-induced prothrombotic immune thrombocytopenia and anaphylaxis, have been described raising great concerns on the safety of some widely spread vaccines. More data need to be collected with further and more detailed analysis. The overall risk of such severe adverse reactions remains extremely low, and the benefits of the existing vaccines in combating the widespread threat of COVID-19 continue to outweigh the risk of their side effects. Elsevier Inc. 2021 2021-04-27 /pmc/articles/PMC8076732/ /pubmed/34518015 http://dx.doi.org/10.1016/j.clindermatol.2021.04.001 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | COVID-19: Important Updates and Developments Bogdanov, Georgi Bogdanov, Ivan Kazandjieva, Jana Tsankov, Nikolai Cutaneous adverse effects of the available COVID-19 vaccines |
title | Cutaneous adverse effects of the available COVID-19 vaccines |
title_full | Cutaneous adverse effects of the available COVID-19 vaccines |
title_fullStr | Cutaneous adverse effects of the available COVID-19 vaccines |
title_full_unstemmed | Cutaneous adverse effects of the available COVID-19 vaccines |
title_short | Cutaneous adverse effects of the available COVID-19 vaccines |
title_sort | cutaneous adverse effects of the available covid-19 vaccines |
topic | COVID-19: Important Updates and Developments |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076732/ https://www.ncbi.nlm.nih.gov/pubmed/34518015 http://dx.doi.org/10.1016/j.clindermatol.2021.04.001 |
work_keys_str_mv | AT bogdanovgeorgi cutaneousadverseeffectsoftheavailablecovid19vaccines AT bogdanovivan cutaneousadverseeffectsoftheavailablecovid19vaccines AT kazandjievajana cutaneousadverseeffectsoftheavailablecovid19vaccines AT tsankovnikolai cutaneousadverseeffectsoftheavailablecovid19vaccines |